Anterior Cervical Bisegmental Interbody Fusion with Titanium Cage(RABEA) in Degenerative Cervical Disease: Comparative Analysis with Monosegmental Interbody Fusion.
- Author:
Seung KIM
1
;
Tae Sung KIM
;
Jun Seok KOH
;
Young Jin LIM
;
Gook Ki KIM
;
Bong Arm RHEE
Author Information
1. Department of Neurosurgery, School of Medicine, Kyung-Hee University, Seoul, Korea. Neuroks@hanmail.net
- Publication Type:Original Article
- Keywords:
Titanium cage;
RABEA;
Interbody fusion;
Two-level degenerative cervical disease
- MeSH:
Diskectomy;
Humans;
Titanium*
- From:Journal of Korean Neurosurgical Society
2003;34(5):440-444
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: It is not uncommon to perform anterior discectomy for two adjacent disc levels in degenerative cervical disease due to diagnostic problems. The purpose of this study is to assess the effectiveness of titanium cage(RABEA) applied to two-level cervical degenerative disc disease, which is compared with the result of fusion with the same cage for one-level disc disease. METHODS: Between January 1999 and March 2003, 52 patients with degenerative cervical disease underwent anterior discectomy and interbody fusion with titanium cage(RABEA). Among them, 23 patients could be followed-up for more than 1 year. Ten patients received interbody fusion at one disc level(Group A), and 13 patients at two adjacent disc levels(Group B). Clinical outcome, fusion rate, disc space height and change of lordotic angle were analyzed in both groups. RESULTS: Clinical outcome according to Odom's criteria was excellent and good in 9(90%) of Group A and 11(84.6%) of Group B. The bone fusion rate of Group B was slightly lower than that of Group A. The height of disc space was well maintained until 1 year postoperatively in both groups. The change of the cervical lordotic angle has no significant difference between the two groups. CONCLUSION: Interbody fusion with titanium cage(RABEA) for two-level degenerative cervical disease may be an acceptable treatment modality due to relatively good clinical outcome despite slightly low fusion rate.
